Frank Rimerman Advisors LLC Increases Stock Position in Agilent Technologies, Inc. (NYSE:A)

Frank Rimerman Advisors LLC boosted its stake in Agilent Technologies, Inc. (NYSE:A) by 18.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,630 shares of the medical research company’s stock after purchasing an additional 258 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Agilent Technologies were worth $219,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of A. Madison Investment Advisors LLC bought a new stake in shares of Agilent Technologies in the 4th quarter worth about $94,051,000. Massachusetts Financial Services Co. MA increased its holdings in shares of Agilent Technologies by 3.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company’s stock worth $2,314,784,000 after buying an additional 525,214 shares during the last quarter. FMR LLC increased its holdings in shares of Agilent Technologies by 62.2% in the 3rd quarter. FMR LLC now owns 1,287,665 shares of the medical research company’s stock worth $191,193,000 after buying an additional 493,947 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Agilent Technologies in the 4th quarter worth about $48,172,000. Finally, Worldquant Millennium Advisors LLC bought a new stake in shares of Agilent Technologies in the 3rd quarter worth about $49,449,000.

Insider Transactions at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Agilent Technologies Price Performance

Shares of A opened at $122.63 on Tuesday. The company has a 50 day moving average price of $137.99 and a 200-day moving average price of $137.82. Agilent Technologies, Inc. has a fifty-two week low of $117.17 and a fifty-two week high of $155.35. The stock has a market capitalization of $34.96 billion, a PE ratio of 28.19, a PEG ratio of 3.40 and a beta of 1.11. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The firm had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Equities analysts predict that Agilent Technologies, Inc. will post 5.57 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be given a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.81%. Agilent Technologies’s payout ratio is presently 22.76%.

Analysts Set New Price Targets

A has been the topic of several analyst reports. Citigroup upped their price target on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday, December 19th. Sanford C. Bernstein cut their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Wells Fargo & Company cut their price target on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a report on Monday, December 9th. Finally, Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $135.00 to $145.00 in a report on Monday, February 10th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $146.15.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.